clinical trial · NCT01658462
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
Centre Oscar Lambret·phase2·completed·n = 51
Breast CancerDocetaxelNintedanibDocetaxel: increase of the dose
brief summary
National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy / Second-line chemotherapy for locally recurrent or metastatic breast cancer.
started
May 1, 2013
primary completion
Dec 31, 2016
completion
Oct 30, 2017
last updated
Mar 16, 2026
detailed description
Patients will be stratified at randomization according to first-line chemotherapy / Second-line chemotherapy for metastatic or locally recurrent breast cancer
Treatment until progression or unacceptable toxicity Visits are planned every 3 weeks during treatment and every 3 months after end of treatment or patient's withdrawal
official title
A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol